(Q38394590)
Statements
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial (English)
Sinem Kilic
Arnoud W J Van't Hof
Jurrien Ten Berg
Ana Ayesta Lopez
Uwe Zeymer
Martial Hamon
Louis Soulat
Debra Bernstein
Efthymios N Deliargyris